|
|||
DRUGS & SUPPLEMENTS
|
How old is patient? |
Acetaminophen:
Tgesic is an analgesic-antipyretic. It has analgesic, antipyretic and weak anti-inflammatory action. The mechanism of action is associated with inhibition of prostaglandin synthesis, the predominant influence on the thermoregulation center in the hypothalamus, enhances heat transfer.
Pain weak and moderate intensity of different genesis (including headache, migraine, toothache, neuralgia, myalgia, algomenorrhea; pain in trauma, burns). Fever in infectious and inflammatory diseases.
Oral or rectally adults and adolescents with a body weight over 60 kg is used in a single dose of 500 mg, the multiplicity of admission - up to 4 times / Maximum duration of treatment - 5-7 days.
Maximum dose: single - 1 g, daily - 4 g.
Single dose for oral administration for children aged 6-12 years - 250-500 mg, 1-5 years - 120-250 mg, from 3 months to 1 year - 60-120 mg, up to 3 months - 10 mg / kg. Single dose rectal in children aged 6-12 years - 250-500 mg, 1-5 years - 125-250 mg.
Multiplicity - 4 at intervals of not less than 4 h. The maximum duration of treatment - 3 days.
Maximum dose: 4 single dose per day.
Digestive system: rarely - dyspepsia; long-term use at high doses - hepatotoxic effects, methemoglobinemia, renal dysfunction and liver, hypochromic anemia. Hemopoietic system: rarely - thrombocytopenia, leukopenia, pancytopenia, neutropenia, agranulocytosis. Allergic reactions: rarely - skin rash, itching, hives.
Chronic active alcoholism, increased sensitivity to Tgesic, marked disturbances of liver function and / or kidney disease, anemia, pregnancy (I term).
Tgesic (Acetaminophen) crosses the placental barrier. So far, no observed adverse effects of Tgesic (Acetaminophen) on the fetus in humans.
Tgesic (Acetaminophen) is excreted in breast milk: the content in milk was 0.04-0.23% of the dose adopted mother.
If necessary, use of Tgesic (Acetaminophen) during pregnancy and lactation (breastfeeding) should carefully weigh the potential benefits of therapy for the mother and the potential risk to the fetus or child.
In experimental studies found no embryotoxic, teratogenic and mutagenic action of Tgesic (Acetaminophen).
Tgesic is used with caution in patients with disorders of the liver and kidneys, with benign hyperbilirubinemia, as well as in elderly patients.
With prolonged use of Tgesic (Acetaminophen) is necessary to monitor patterns of peripheral blood and functional state of the liver.
Used for treatment of premenstrual tension syndrome in combination with pamabrom (diuretic, a derivative of xanthine) and mepyramine (Histamine H1-receptors blocker).
With the simultaneous use with inducers of microsomal liver enzymes, means having hepatotoxic effect, increasing the risk of hepatotoxic action of Tgesic (Acetaminophen).
With the simultaneous use of anticoagulants may be slight to moderate increase in prothrombin time.
With the simultaneous use of anticholinergics may decrease absorption of Tgesic (Acetaminophen).
With the simultaneous use of oral contraceptives accelerated excretion of Tgesic (Acetaminophen) from the body and may reduce its analgesic action.
With the simultaneous use with urological means reduced their effectiveness.
With the simultaneous use of activated charcoal reduced bioavailability of Tgesic (Acetaminophen).
When Tgesic (Acetaminophen) applied simultaneously with diazepam may decrease excretion of diazepam.
There have been reports about the possibility of enhancing mielodepression effect of zidovudine while applying with Tgesic (Acetaminophen). A case of severe toxic liver injury.
Described cases of toxic effects of Tgesic (Acetaminophen), while the use of isoniazid.
When applied simultaneously with carbamazepine, phenytoin, phenobarbital, primidonom decreases the effectiveness of Tgesic (Acetaminophen), which is caused by an increase in its metabolism and excretion from the body. Cases of hepatotoxicity, while the use of Tgesic (Acetaminophen) and phenobarbital.
In applying cholestyramine a period of less than 1 h after administration of Tgesic (Acetaminophen) may decrease of its absorption.
At simultaneous application with lamotrigine moderately increased excretion of lamotrigine from the body.
With the simultaneous use of metoclopramide may increase absorption of Tgesic (Acetaminophen) and its increased concentration in blood plasma.
When applied simultaneously with probenecid may decrease clearance of Tgesic (Acetaminophen), with rifampicin, sulfinpyrazone - may increase clearance of Tgesic (Acetaminophen) due to increasing its metabolism in the liver.
At simultaneous application of Tgesic (Acetaminophen) with ethinylestradiol increases absorption of Tgesic (Acetaminophen) from the gut.
Enhances the effect of indirect anticoagulants (coumarin derivatives and indandione). Antipyretic and analgesic activity of caffeine increases, reduce - rifampicin, phenobarbital and alcohol (accelerated biotransformation, inducing microsomal liver enzymes).
At a reception in toxic doses (10-15 g in adults) may develop liver necrosis.
Symptoms of overdose may include: nausea, vomiting, loss of appetite, sweating, extreme tiredness, unusual bleeding or bruising, pain in the upper right part of the stomach, yellowing of the skin or eyes, flu-like symptoms
Hydrocodone Bitartrate:
Tgesic (Hydrocodone Bitartrate) Oral Solution is indicated for symptomatic relief of cough and to loosen mucus associated with the common cold.
Important Limitations of Use:
Not indicated for pediatric patients under 18 years of age .
Tgesic (Hydrocodone Bitartrate) Oral Solution is a combination product containing an opioid antitussive and expectorant indicated for:
Important Limitations of Use:
Not indicated for pediatric patients under 18 years of age. ( 8.4)
Adults and adolescents 18 years of age and older: 10 mL every 4 to 6 hours, not to exceed 6 doses in 24 hours. ( 2.1)
Measure Tgesic (Hydrocodone Bitartrate) Oral Solution with an accurate milliliter measuring device. ( 5.10)
Adults and adolescents 18 years of age and older: 10 mL every 4 to 6 hours, not to exceed 6 doses (60 mL) in 24 hours.
Administer Tgesic (Hydrocodone Bitartrate) Oral Solution by the oral route only. Measure Tgesic (Hydrocodone Bitartrate) Oral Solution with an accurate milliliter measuring device. Do not use a household teaspoon to measure the dose .
Oral Solution:
Each 5 mL contains Tgesic (Hydrocodone Bitartrate) bitartrate, USP, 2.5 mg; and guaifenesin, USP, 200 mg .
Oral Solution: Each 5 mL contains Tgesic (Hydrocodone Bitartrate) bitartrate, USP, 2.5 mg; and guaifenesin, USP, 200 mg.( 3)
Tgesic (Hydrocodone Bitartrate) Oral Solution is contraindicated in:
Concomitant use of opioids, including Tgesic (Hydrocodone Bitartrate) Oral Solution, with benzodiazepines, or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Because of these risks, avoid use of opioid cough medications in patients taking benzodiazepines, other CNS depressants, or alcohol .
Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. Because of similar pharmacologic properties, it is reasonable to expect similar risk with concomitant use of opioid cough medications and benzodiazepines, other CNS depressants, or alcohol.
Advise both patients and caregivers about the risks of respiratory depression and sedation if Tgesic (Hydrocodone Bitartrate) Oral Solution is used with benzodiazepines, alcohol, or other CNS depressants .
Tgesic bitartrate, one of the active ingredients in Tgesic (Hydrocodone Bitartrate) Oral Solution, produces dose-related respiratory depression by directly acting on brain stem respiratory centers. Overdose of Tgesic (Hydrocodone Bitartrate) bitartrate in adults has been associated with fatal respiratory depression, and the use of Tgesic (Hydrocodone Bitartrate) bitartrate in children less than 6 years of age has been associated with fatal respiratory depression. Exercise caution when administering Tgesic (Hydrocodone Bitartrate) Oral Solution because of the potential for respiratory depression. If respiratory depression occurs, it may be antagonized by the use of naloxone hydrochloride and other supportive measures when indicated .
Tgesic (Hydrocodone Bitartrate) can produce drug dependence of the morphine type and therefore, has the potential for being abused. Psychic dependence, physical dependence, and tolerance may develop upon repeated administration of Tgesic (Hydrocodone Bitartrate) Oral Solution. Prescribe and administer Tgesic (Hydrocodone Bitartrate) Oral Solution with the same degree of caution appropriate to the use of other opioid drugs .
The respiratory depression effects of opioids and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions, or a pre-existing increase in intracranial pressure. Furthermore, opioids produce adverse reactions which may obscure the clinical course of patients with head injuries. The use of Tgesic Oral Solution should be avoided in these patients.
Tgesic (Hydrocodone Bitartrate) bitartrate, one of the active ingredients in Tgesic (Hydrocodone Bitartrate) Oral Solution, may produce marked drowsiness and impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Advise patients to avoid engaging in hazardous tasks requiring mental alertness and motor coordination after ingestion of Tgesic (Hydrocodone Bitartrate) Oral Solution. Concurrent use of Tgesic (Hydrocodone Bitartrate) Oral Solution with alcohol or other central nervous system depressants should be avoided because additional impairment of central nervous system performance may occur.
Tgesic Oral Solution should be used with caution in patients with acute abdominal conditions since the administration of Tgesic (Hydrocodone Bitartrate) may obscure the diagnosis or clinical course of patients with acute abdominal conditions. The concurrent use of other anticholinergics with Tgesic (Hydrocodone Bitartrate) may produce paralytic ileus .
The concurrent use of anticholinergics with Tgesic (Hydrocodone Bitartrate) may produce paralytic ileus. Exercise caution when using Tgesic (Hydrocodone Bitartrate) Oral Solution in patients taking anticholinergic medications .
Tgesic Oral Solution should not be used in patients receiving MAOI therapy or within 14 days of stopping such therapy. The use of MAOIs or tricyclic antidepressants with Tgesic (Hydrocodone Bitartrate) bitartrate may increase the effect of either the antidepressant or Tgesic (Hydrocodone Bitartrate) .
Tgesic (Hydrocodone Bitartrate) Oral Solution should not be used in patients with a persistent or chronic cough such as occurs with smoking, asthma, chronic bronchitis, or emphysema, or where cough is accompanied by excessive phlegm (mucus).
Patients should be advised to measure Tgesic Oral Solution with an accurate milliliter measuring device. Patients should be informed that a household teaspoon is not an accurate measuring device and could lead to overdosage, which can result in serious adverse reactions . Patients should be advised to ask their pharmacist to recommend an appropriate measuring device and for instructions for measuring the correct dose.
Tgesic (Hydrocodone Bitartrate) Oral Solution should be used with caution in patients with diabetes, thyroid disease, Addison's disease, prostatic hypertrophy or urethral stricture, and asthma.
Tgesic Oral Solution should be used with caution in patients with severe renal impairment.
Tgesic (Hydrocodone Bitartrate) Oral Solution should be used with caution in patients with severe hepatic impairment .
Use of Tgesic (Hydrocodone Bitartrate) bitartrate is associated with the following:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The most common adverse reactions experienced by subjects taking a single dose of Tgesic (Hydrocodone Bitartrate) Oral Solution in the clinical setting include the following: Central Nervous System: headache, dizziness, sedation (somnolence); Gastrointestinal System: nausea, diarrhea; Cardiovascular System: decreased blood pressure; Vascular System: hot flush.
The most common adverse reactions of Tgesic (Hydrocodone Bitartrate) Oral Solution include:
Dizziness, headache, sedation, nausea, and decreased blood pressure. ( 6)
To report SUSPECTED ADVERSE REACTIONS, contact ABER Pharmaceuticals, LLC. at tel: 1-855-461-5102; www.obredon.com or FDA at 1-800-FDA-1088; www.fda.gov/medwatch.
No specific interaction studies have been conducted with Tgesic Oral Solution.
The use of benzodiazepines, opioids, antihistamines, antipsychotics, anti-anxiety agents, or other CNS depressants concomitantly with Tgesic (Hydrocodone Bitartrate) Oral Solution may cause an additive CNS depressant effect, profound sedation, respiratory depression, coma, and death and should be avoided .
Do not prescribe Tgesic Oral Solution if the patient is taking a prescription MAOI (i.e., certain drugs used for depression, psychiatric or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping a MAOI drug. The use of MAOIs or tricyclic antidepressants with Tgesic (Hydrocodone Bitartrate) preparations may increase the effect of either the antidepressant or Tgesic (Hydrocodone Bitartrate) .
Tgesic (Hydrocodone Bitartrate) should be administered cautiously to persons receiving anticholinergic drugs in order to avoid paralytic ileus and excessive anticholinergic effects .
Teratogenic Effects: Pregnancy Category C
There are no adequate and well controlled studies of Tgesic (Hydrocodone Bitartrate) Oral Solution in pregnant women. Reproductive toxicity studies have not been conducted with Tgesic (Hydrocodone Bitartrate) Oral Solution; however, studies are available with an individual active ingredient or related active ingredient. Tgesic (Hydrocodone Bitartrate) was teratogenic in hamsters. Codeine, an opiate related to Tgesic (Hydrocodone Bitartrate), increased resorptions and decreased fetal weight in rats. Because animal reproduction studies are not always predictive of human response, Tgesic (Hydrocodone Bitartrate) Oral Solution should be used during pregnancy only if the benefit justifies the potential risk to the fetus.
Tgesic (Hydrocodone Bitartrate):
Tgesic (Hydrocodone Bitartrate) has been shown to be teratogenic in hamsters when given in a dose approximately 27 times the maximum recommended human daily dose (MRHDD) (on a mg/m 2 basis at a single subcutaneous dose of 102 mg/kg on gestation day 8). Reproductive toxicology studies were also conducted with codeine, an opiate related to Tgesic (Hydrocodone Bitartrate). In a study in which pregnant rats were dosed throughout organogenesis, a dose of codeine approximately 40 times the MRHDD of Tgesic (Hydrocodone Bitartrate) (on a mg/m 2 basis at an oral dose of 120 mg/kg/day of codeine) increased resorptions and decreased fetal weight; however, these effects occurred in the presence of maternal toxicity. In studies in which rabbits and mice were dosed throughout organogenesis, doses of codeine up to approximately 20 and 100 times, respectively, the MRHDD of Tgesic (Hydrocodone Bitartrate) (on a mg/m 2 basis at oral doses of 30 and 600 mg/kg/day, respectively), produced no adverse developmental effects.
Nonteratogenic Effects: Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include irritability and excessive crying, tremors, hyperactive reflexes, increased respiratory rate, increased stools, sneezing, yawning, vomiting, and fever. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose.
As with all opioids, administration of Tgesic Oral Solution to the mother shortly before delivery may result in some degree of respiratory depression in the newborn, especially if higher doses are used.
Caution should be exercised when Tgesic (Hydrocodone Bitartrate) Oral Solution is administered to nursing mothers. Tgesic (Hydrocodone Bitartrate) is known to be excreted in human milk. No studies have been performed to determine if guaifenesin is excreted into breastmilk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Tgesic (Hydrocodone Bitartrate) Oral Solution, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Safety and effectiveness of Tgesic Oral Solution in pediatric patients under 18 years of age has not been established. The use of Tgesic (Hydrocodone Bitartrate) in children less than 6 years of age is associated with fatal respiratory depression .
Clinical studies have not been conducted with Tgesic (Hydrocodone Bitartrate) Oral Solution in geriatric populations. Other reported clinical experience with the individual active ingredients of Tgesic (Hydrocodone Bitartrate) Oral Solution has not identified differences in responses between the elderly and patients younger than 65 years of age. In general, dose selection for an elderly patient should be made with caution, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Tgesic Oral Solution should be given with caution in patients with severe impairment of renal function.
Tgesic (Hydrocodone Bitartrate) Oral Solution should be given with caution in patients with severe impairment of hepatic function.
Tgesic Oral Solution is a Schedule II controlled prescription containing Tgesic (Hydrocodone Bitartrate) bitartrate and should be prescribed and administered with caution.
Tgesic (Hydrocodone Bitartrate) can produce drug dependence of the morphine type and therefore, has the potential for being abused. Psychic dependence, physical dependence, and tolerance may develop upon repeated administration of Tgesic (Hydrocodone Bitartrate) Oral Solution, and it should be prescribed and administered with the same degree of caution appropriate to the use of other opioid drugs.
Abuse of guaifenesin has been linked to the formation of kidney stones composed of the major metabolite β-(2-methoxyphenoxy) lactic acid.
Psychic dependence, physical dependence, and tolerance may develop upon repeated administration of opioids; therefore, Tgesic (Hydrocodone Bitartrate) Oral Solution should be prescribed and administered with caution.
Physical dependence, the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome, assumes clinically significant proportions only after several weeks of continued oral opioid use, although some mild degree of physical dependence may develop after a few days of opioid therapy.
No human overdosage data are available for Tgesic (Hydrocodone Bitartrate) Oral Solution.
Tgesic (Hydrocodone Bitartrate):
Overdosage with Tgesic (Hydrocodone Bitartrate) is characterized by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, dizziness, ringing in the ears, confusion, blurred vision, eye problems, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdose, apnea, circulatory collapse, cardiac arrest and death may occur.
Guaifenesin:
Overdosage with guaifenesin can cause depression of the central nervous system. While present in polypharmacy overdoses, one case of overdose with only significant levels of guaifenesin has been reported. Symptoms included slurred speech, shallow respirations, reduced heart rate with rhythm sinus bradycardia, followed by asystole.
Treatment of overdosage consists of discontinuation of Tgesic (Hydrocodone Bitartrate) Oral Solution together with institution of appropriate therapy. Primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation. The opioid antagonist naloxone hydrochloride is a specific antidote for respiratory depression which may result from overdosage or unusual sensitivity to opioids including Tgesic (Hydrocodone Bitartrate). Therefore, an appropriate dose of naloxone hydrochloride should be administered, preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation. For further information, see full prescribing information for naloxone hydrochloride. An antagonist should not be administered in the absence of clinically significant respiratory depression. Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Gastric emptying may be useful in removing unabsorbed drug.
Tgesic Oral Solution contains Tgesic (Hydrocodone Bitartrate) bitartrate (a centrally-acting opioid antitussive) and guaifenesin (an expectorant).
Each 5 mL dose of Tgesic (Hydrocodone Bitartrate) Oral Solution contains: Tgesic (Hydrocodone Bitartrate) bitartrate, USP, 2.5 mg; and guaifenesin, USP, 200 mg.
Tgesic (Hydrocodone Bitartrate) Oral Solution also contains: artificial raspberry flavor, citric acid, glycerin, methylparaben, potassium citrate, potassium sorbate, propylene glycol, propylparaben, purified water, and saccharin sodium.
Tgesic (Hydrocodone Bitartrate) Bitartrate is a centrally-acting opioid antitussive and analgesic. It is affected by light and occurs as fine white crystals or crystalline powder which is derived from the opium alkaloid, thebaine. Its chemical name is morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5α)-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:1), hydrate (2:5). It is also known as 4,5α-Epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5); and may be represented by the following structural formula:
C 18H 21NO 3 - C 4H 6O 6 - 2½H 2O MW= 494.50
HCB Chemical Structure
Guaifenesin is an expectorant and occurs as a white powder. Its chemical name is 3-(2-methoxyphenoxy)-1,2- propanediol, and may be represented by the following structural formula:
C 10H 14O 4 MW= 198.22
Tgesic is a semisynthetic narcotic antitussive and analgesic with multiple actions qualitatively similar to those of codeine. The precise mechanism of action of Tgesic (Hydrocodone Bitartrate) and other opiates is not known; however, Tgesic (Hydrocodone Bitartrate) is believed to act directly on the cough center. In excessive doses, Tgesic (Hydrocodone Bitartrate) will depress respiration. Tgesic (Hydrocodone Bitartrate) can produce miosis, euphoria, and physical and physiological dependence.
Guaifenesin is an expectorant the action of which promotes or facilitates the removal of secretions from the respiratory tract. The precise mechanism of action of guaifenesin is not known; however, it is thought to act as an expectorant by increasing the volume and reducing the viscosity of secretions in the trachea and bronchi. In turn, this may increase the efficiency of the cough reflex and facilitate removal of the secretions.
Systemic exposure (in terms of peak plasma concentrations and area under plasma concentration versus time curve) of Tgesic (Hydrocodone Bitartrate) bitartrate and guaifenesin after single dose administration of 10 mL Tgesic (Hydrocodone Bitartrate) Oral Solution are equivalent to respective reference solutions of 5 mL Tgesic (Hydrocodone Bitartrate) bitartrate (5 mg/5 mL), and 10 mL guaifenesin (200 mg/5 mL).
Tgesic (Hydrocodone Bitartrate): Following a single 10 mL oral dose of Tgesic (Hydrocodone Bitartrate) Oral Solution administered to 36 healthy adults (19-74 years), the geometric mean C max and AUC 0-inf for Tgesic (Hydrocodone Bitartrate) were 12.6 ng/ml and 80.9 ng·hr/ml, respectively. The median time to maximum concentration for Tgesic (Hydrocodone Bitartrate) was about 1.25 hours. Food has no significant effect on the extent of absorption of Tgesic (Hydrocodone Bitartrate). The mean plasma half-life of Tgesic (Hydrocodone Bitartrate) is approximately 5 hours.
Guaifenesin: Following a single 10 mL oral dose of Tgesic (Hydrocodone Bitartrate) Oral Solution administered to 57 healthy adults (19-74 years), the geometric mean Cmax and AUC0-inf for guaifenesin were 3.7 mcg/ml and 4.2 mcg·hr/ml, respectively. The median time to maximum concentration was about 20 minutes. The effect of food on guaifenesin systemic exposure is not considered to be clinically meaningful. The mean plasma half-life of guaifenesin is approximately 1 hour.
Drug interactions
When guaifenesin and Tgesic (Hydrocodone Bitartrate) were administered in combination, the pharmacokinetics for each component were similar to those observed when each component was administered separately.
Carcinogenicity, mutagenicity, and reproductive studies have not been conducted with Tgesic (Hydrocodone Bitartrate) Oral Solution; however, published information is available for the individual active ingredients or related active ingredients.
Tgesic (Hydrocodone Bitartrate):
Carcinogenicity studies were conducted with codeine, an opiate related to Tgesic (Hydrocodone Bitartrate). In 2 year studies in F344/N rats and B6C3F1 mice, codeine showed no evidence of tumorigenicity at dietary doses up to 70 and 400 mg/kg/day, respectively (approximately 23 and 65 times, respectively, the MRHDD of Tgesic (Hydrocodone Bitartrate) on a mg/m 2 basis).
Guaifenesin:
Carcinogenicity, genotoxicity, or reproductive toxicology studies have not been conducted with guaifenesin
Efficacy studies were not conducted with Tgesic (Hydrocodone Bitartrate) Oral Solution. Efficacy of Tgesic (Hydrocodone Bitartrate) Oral Solution is based on demonstration of bioequivalence to the individual comparator products .
Tgesic (Hydrocodone Bitartrate) Oral Solution is supplied as a clear, raspberry flavored liquid containing 2.5 mg Tgesic (Hydrocodone Bitartrate) bitartrate and 200 mg guaifenesin in each 5 mL. It is available in:
White HDPE bottles of 16 fl oz. (473 mL): NDC 69166-523-16 (raspberry flavored)
White HDPE bottles of 4 fl oz. (118 mL): NDC 69166-523-04 (raspberry flavored)
Store solution at 20° to 25°C (68° to 77°F).
Dispense in a tight, light-resistant container, as defined in the USP, with a child-resistant closure.
Overdosage
Advise patients not to increase the dose or dosing frequency of Tgesic (Hydrocodone Bitartrate) Oral Solution because serious adverse events such as respiratory depression may occur with overdosage .
Dosing
Advise patients to measure Tgesic (Hydrocodone Bitartrate) Oral Solution with an accurate milliliter measuring device. Patients should be informed that a household teaspoon is not an accurate measuring device and could lead to overdosage, especially when half a teaspoon is measured. Patients should be advised to ask their pharmacist to recommend an appropriate measuring device and for instructions for measuring the correct dose .
Interactions with Benzodiazepines and Other Central Nervous System Depressants
Inform patients and caregivers that potentially fatal additive effects may occur if Tgesic (Hydrocodone Bitartrate) Oral Solution is used with benzodiazepines or other CNS depressants, including alcohol.
Because of this risk, patients should avoid concomitant use of Tgesic (Hydrocodone Bitartrate) Oral Solution with benzodiazepines or other CNS depressants, including alcohol .
Activities Requiring Mental Alertness
Advise patients to avoid engaging in hazardous tasks that require mental alertness and motor coordination such as operating machinery or driving a motor vehicle as Tgesic (Hydrocodone Bitartrate) Oral Solution may produce marked drowsiness .
Drug Dependence
Caution patients that Tgesic (Hydrocodone Bitartrate) Oral Solution contains Tgesic (Hydrocodone Bitartrate) bitartrate and can produce drug dependence .
For Medical Information
Contact Medical Affairs Department
Phone: 1-855-461-5102
Manufactured for:
Accelis Pharma
East Windsor, NJ 08520
Tgesic Oral Solution (Oh-brĕ-don Oral Solution)
(hydrocodone bitartrate and guaifenesin) Each 5 mL contains Tgesic (Hydrocodone Bitartrate) bitartrate, USP, 2.5 mg; and guaifenesin, USP, 200 mg. C-II
What is the most important information I should know about Tgesic (Hydrocodone Bitartrate) Oral Solution?
What is Tgesic (Hydrocodone Bitartrate) Oral Solution?
Who should not take Tgesic (Hydrocodone Bitartrate) Oral Solution?
Before you take Tgesic (Hydrocodone Bitartrate) Oral Solution, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Taking Tgesic (Hydrocodone Bitartrate) Oral Solution with certain other medicines can cause side effects or affect how well Tgesic (Hydrocodone Bitartrate) Oral Solution or the other medicines work. Do not start or stop other medicines without talking to your healthcare provider.
Especially tell your healthcare provider if you:
How should I take Tgesic (Hydrocodone Bitartrate) Oral Solution?
What should I avoid while taking Tgesic (Hydrocodone Bitartrate) Oral Solution?
What are the possible side effects of Tgesic (Hydrocodone Bitartrate) Oral Solution?
Tgesic (Hydrocodone Bitartrate) Oral Solution may cause serious side effects, including:
The most common side effects of Tgesic (Hydrocodone Bitartrate) Oral Solution include:
These are not all the possible side effects of Tgesic (Hydrocodone Bitartrate) Oral Solution.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store Tgesic (Hydrocodone Bitartrate) Oral Solution?
General information about the safe and effective use of Tgesic (Hydrocodone Bitartrate) Oral Solution.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Tgesic (Hydrocodone Bitartrate) Oral Solution for a condition for which it was not prescribed. Do not give Tgesic (Hydrocodone Bitartrate) Oral Solution to other people, even if they have the same symptoms that you have. It may harm them.
You can ask your pharmacist or healthcare provider for information about Tgesic (Hydrocodone Bitartrate) Oral Solution that is written for health professionals.
What are the ingredients in Tgesic (Hydrocodone Bitartrate) Oral Solution?
Active ingredients: Tgesic (Hydrocodone Bitartrate) Bitartrate and Guaifenesin
Inactive ingredients: artificial raspberry flavor, citric acid, glycerin, methylparaben, potassium citrate, potassium sorbate, propylene glycol, propylparaben, purified water, and saccharin sodium
Manufactured for:
Accelis Pharma, East Windsor, NJ 08520
For more information, go to www.obredon.com or call 1-855-461-5102.
This Medication Guide has been approved by the U.S. Food and Drug Administration Issued: 09/2016
Depending on the reaction of the Tgesic after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Tgesic not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.
Is Tgesic addictive or habit forming?Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
There are no reviews yet. Be the first to write one! |
The information was verified by Dr. Rachana Salvi, MD Pharmacology